Aquestive Therapeutics filed an investor presentation for the Jefferies Global Healthcare Conference on November 16, 2026. The presentation provides updates on the regulatory status of Anaphylm (epinephrine) sublingual film, including the March 16, 2027 PDUFA goal date, and the commercial launch strategy for the product if approved.
Aquestive Therapeutics filed a corporate investor presentation for November 2026 to be used in meetings with institutional investors and analysts. The presentation provides updates on the regulatory status of Anaphylm (sublingual epinephrine) following its NDA resubmission, which has a PDUFA goal date of March 16, 2027, and the development of its AdrenaVerse pipeline including AQST-108.
Aquestive Therapeutics filed a corporate investor presentation dated September 23, 2026, to be used in meetings with institutional investors and analysts. The presentation provides updates on the company's AdrenaVerse pipeline, including the regulatory status of Anaphylm (epinephrine) sublingual film following its NDA resubmission to the FDA and the development of AQST-108 for dermatologic indications.